Research programme: oligonucleotide therapeutics - Alexion AstraZeneca Rare Disease/JCR Pharmaceuticals
Latest Information Update: 04 Jan 2024
At a glance
- Originator Alexion AstraZeneca Rare Disease; JCR Pharmaceuticals
- Class Oligonucleotides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified